DEA schedule
Is Adbry a controlled substance?
Adbry contains tralokinumab. Federal schedule from the FDA NDC directory, checked against the DEA controlled substances list.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
No. Adbry (tralokinumab) is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and tralokinumab is not on the DEA controlled substances list.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Adbry?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Schedule check
| Source | What it lists |
|---|---|
| FDA NDC directory | 2 prescription listings from 1 labelers, none with a DEA schedule |
| DEA controlled substances list | tralokinumab is not on the list |
Adbry NDC listings
Questions
Is Adbry a controlled substance?
No. Adbry (tralokinumab) is not a federally controlled substance. None of its FDA NDC listings carries a DEA schedule, and tralokinumab is not on the DEA controlled substances list.
Is Adbry a narcotic?
No. Adbry (tralokinumab) is not on the DEA controlled substances list, so the DEA does not classify it as a narcotic. Its FDA established pharmacologic class is Interleukin-13 Antagonist.
Does this page cover state schedules?
No. This page reports the federal schedule only. Some states schedule drugs on their own; check your state board of pharmacy.